Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00028548 · ClinicalTrials.gov registry record · Phase 1

XK469 in Treating Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT00028548: Completed Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.

NCT00028548 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00028548, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of XK469 in treating patients who have advanced solid tumors.

Interventions

  • DRUG R(+)XK469

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2002-01
Est. Completion 2006-12
Phase Phase 1

What the finished NCT00028548 record still lists

NCT00028548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 1 intervention - of which R(+)XK469 is the first listed.

NCT00028548 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00028548 about?

NCT00028548 is a clinical study titled "XK469 in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of XK469 in treating patients who have advanced solid tumors.

What is the current status of trial NCT00028548?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2002-01. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00028548?

The interventions under investigation include: R(+)XK469 (DRUG).

Who is sponsoring clinical trial NCT00028548?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00028548's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00028548, the US trial registry maintained by the National Library of Medicine. NCT00028548 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.